Skip to main content
Premium Trial:

Request an Annual Quote

BD s Q1 Revenues Up 9 Percent, Led by Biosciences, Medical Segment

NEW YORK, Jan. 27 (GenomeWeb News) - Led by double-digit revenue growth in its biosciences and medical segments, Becton Dickinson this week reported $1.3 billion in the first quarter, up 9 percent over $1.2 billion in revenues for the year-ago period.

 

The company's biosciences segment had revenues of $181 million, up 15 percent over the year-ago period's $157 million. The rise in revenues was attributed primarily to sales of the company's FacsCanto analyzer, and the FacsAria cell sorter, and sales of flow cytometry reagents to the clinical and research markets.

 

BD Medical had sales of $694 million, up 11 percent over the year-ago period's $627 million in revenue, while BD Diagnostics had sales of $414 million, up 3 percent over the previous period's $401 million in sales.

 

R&D expenditures were up 6.5 percent to $62 million for the period, compared to $58 million last year.

 

BD's operating income for the quarter was $250 million, up 48 percent over $168 million in Q1 FY '04.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.